Exchange & Returns Information
Review Details
(0)
| Generic For | AVASTIN |
|---|---|
| Active Ingredient | BEVACIZUMAB |
| Strength | 100MG |
| Manufacturer | HETERO DRUGS |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 96.00 | $ 96.00 |
$ 81.60
Apply ZARVY26 (-15%)
You save $ 14.40
|
||
| 2 BOXES - 2 VIALS | $ 100.00 | $ 200.00 |
$ 170.00
Apply ZARVY26 (-15%)
You save $ 30.00
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 101.33 | $ 304.00 |
$ 258.40
Apply ZARVY26 (-15%)
You save $ 45.60
|
Reference information will be available soon.
Cizumab 100 is a 100mg/4ml injectable formulation of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It works by binding VEGF-A, thereby preventing its interaction with VEGF receptors on the surface of endothelial cells. This inhibition halts angiogenesis—the formation of new blood vessels—which is essential for tumor growth and metastasis. Bevacizumab is not a standalone treatment but is used in combination with chemotherapy across various advanced solid tumors. It has demonstrated clinical benefit in prolonging overall survival (OS), progression-free survival (PFS), and controlling disease-related symptoms such as edema, hemorrhage, and tumor perfusion instability.
AntiCancer Drugs > Colorectal Cancer
Used in combination with chemotherapy regimens like FOLFOX, FOLFIRI, or CAPEOX in first- and second-line settings for metastatic colorectal cancer. It enhances drug delivery by normalizing tumor vasculature and improves overall survival.
Non-Small Cell Lung Cancer (non-squamous)
Administered with platinum-based doublets (e.g., carboplatin + paclitaxel) as a first-line option for unresectable or metastatic non-squamous NSCLC. It has shown particular benefit in cases with high angiogenic signaling or cerebral metastases.
Glioblastoma
Indicated for recurrent glioblastoma multiforme (GBM), especially where steroid-refractory cerebral edema and mass effect are present. It reduces peritumoral edema and improves neurologic symptoms by suppressing VEGF overexpression.
Renal Cell Carcinoma
Used in combination with interferon-alfa in metastatic clear cell RCC. It represents one of the earliest anti-VEGF therapies used in systemic treatment for kidney cancer.
Cervical Cancer
Combines with topotecan + cisplatin or paclitaxel in persistent, recurrent, or metastatic cases. Clinical trials have shown improved survival when added to cytotoxic chemotherapy.
Ovarian, Fallopian Tube, Peritoneal Cancers
Approved for both front-line and recurrent platinum-sensitive and platinum-resistant cases. Often combined with carboplatin + paclitaxel or pegylated liposomal doxorubicin (PLD). Also indicated as maintenance therapy following initial treatment response.
Hepatocellular Carcinoma
Given in combination with atezolizumab for advanced or unresectable HCC. This duo forms a standard first-line immunotherapy regimen as per international guidelines.
Binds VEGF-A to block angiogenesis, tumor vascularization, and nutrient delivery
Normalizes leaky tumor vasculature, improving chemotherapy penetration
Reduces vascular permeability, edema, and intracranial pressure
Synergizes with multiple chemotherapeutic backbones across tumor types
Colorectal Cancer
→ First-line (with IFL): 5 mg/kg IV q2w
→ First-line (with FOLFOX4): 10 mg/kg IV q2w
→ Second-line: 5 mg/kg IV q2w or 7.5 mg/kg IV q3w
Use: For metastatic colorectal cancer as part of cytotoxic combinations
Non-Small Cell Lung Cancer
→ 15 mg/kg IV q3w with carboplatin + paclitaxel
Use: First-line treatment for non-squamous NSCLC
Glioblastoma
→ 10 mg/kg IV q2w
Use: Recurrent glioblastoma, especially in steroid-resistant cases
Renal Cell Carcinoma
→ 10 mg/kg IV q2w with interferon alfa
Use: Metastatic RCC with clear cell histology
Cervical Cancer
→ 15 mg/kg IV q3w with paclitaxel + cisplatin or topotecan
Use: Persistent, recurrent, or metastatic cervical cancer
Ovarian / Fallopian / Peritoneal Cancer
→ Stage III/IV (post-op): 15 mg/kg IV q3w ×6 with carboplatin + paclitaxel → maintenance q3w up to 22 cycles
→ Recurrent – Platinum-Resistant:
▪ 10 mg/kg IV q2w with weekly paclitaxel, PLD, or topotecan
▪ 15 mg/kg IV q3w with q3w topotecan
→ Recurrent – Platinum-Sensitive:
▪ 15 mg/kg IV q3w with carboplatin + paclitaxel (6–8 cycles) or carboplatin + gemcitabine (6–10 cycles) → then maintenance 15 mg/kg IV q3w
Use: For newly diagnosed and relapsed epithelial ovarian and related cancers
Hepatocellular Carcinoma
→ 15 mg/kg IV q3w after 1200 mg atezolizumab IV
Use: Unresectable/metastatic HCC (first-line therapy with atezolizumab)
Administration Instructions:
→ 1st infusion: over 90 minutes
→ 2nd infusion: over 60 minutes
→ Subsequent doses: over 30 minutes if well-tolerated
→ Continue until disease progression or unacceptable toxicity
Store in refrigerator at 2°C–8°C
Do not freeze or shake
Keep in original carton to protect from light
Discard unused portion after opening
Use aseptic technique when handling
Common
hypertension, fatigue, proteinuria, delayed wound healing
Serious
gastrointestinal perforation, arterial thromboembolism, hemorrhage
Others
reversible posterior leukoencephalopathy syndrome (RPLS), neutropenia
Monitoring
BP, urine protein levels, CBC, and signs of bleeding or thrombotic events
Precautions
Hold therapy in patients undergoing surgery; resume after adequate wound healing
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
